均瑤健康(605388.SH):擬使用閒置自有資金購買愛建信託發行的理財產品 交易額度不超3億元
格隆匯9月1日丨均瑤健康(605388.SH)公佈,為進一步提高閒置自有資金的使用效率,在不影響公司日常經營活動、確保資金安全性、流動性的前提下,公司擬使用閒置自有資金購買上海愛建信託有限責任公司(“愛建信託”)發行的理財產品,交易額度不超過人民幣3億元,並可在上述額度內滾動使用,期限自股東大會審議通過之日起1年內有效。
公司控股股東上海均瑤(集團)有限公司(“均瑤集團”)持有上海愛建集團股份有限公司(“愛建集團”)29.80%的股份,均瑤集團為愛建集團控股股東;愛建集團持有愛建信託100%股權。根據《上海證券交易所股票上市規則》的有關規定,公司與愛建信託存在關聯關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.